Document is current
Any future updates will be listed below
-
Authors
Click, Benjamin
Barnes, Edward L.
Cohen, Benjamin L.
Sands, Bruce E.
Hanson, John S.
Rubin, David T.
Dubinsky, Marla C.
Regueiro, Miguel
Gazis, Derek
Crawford, Julie M. https://orcid.org/0000-0001-8976-8558
Long, Millie D.
- License Information
-
More Information
Article History
Received: 26 September 2021
Accepted: 6 February 2022
First Online: 19 February 2022
Declarations
:
: TARGET-IBD is conducted in accordance with good clinical practice requirements and compliance with the ethical principles described in the current revision of the Declaration of Helsinki. All enrolling sites have either central or local Institutional Review Board protocol approval and patient participants undergo informed consent prior to data submission and abstraction. Written informed consent was obtained from participants prior to enrollment into TARGET-IBD.
: No individual data was included.
: Benjamin Click: Takeda—consulting, speakers bureau, Target RWE—consulting. Edward L. Barnes: consultant for AbbVie, Takeda, Gilead, Pfizer, and Target RWE. Benjamin L. Cohen: consulting for AbbVie, Allergan, Target RWE and Sublimity Therapeutics. Bruce Sands: consulting fees from 4D Pharma, Abbvie, Allergan, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer–Ingelheim, Boston Pharmaceuticals, Capella Biosciences, Celgene, Celltrion Healthcare, EnGene, Ferring, Genentech, Gilead, Hoffmann-La Roche, Immunic, Ironwood Pharmaceuticals, Janssen, Lilly, Lyndra, MedImmune, Morphic Therapeutic, Oppilan Pharma, OSE Immunotherapeutics, Otsuka, Palatin Technologies, Pfizer, Progenity, Prometheus Laboratories, Redhill Biopharma, Rheos Medicines, Seres Therapeutics, Shire, Synergy Pharmaceuticals, Takeda, Target RWE, Theravance Biopharma R&D, TiGenix, Vivelix Pharmaceuticals; honoraria for speaking in CME programs from Takeda, Janssen, Lilly, Gilead, Pfizer, Genetech; research funding from Celgene, Pfizer, Takeda, Theravance Biopharma R&D, Janssen. John S. Hanson: Pfizer-Speakers’ Bureau, AbbVie-Speakers’ Bureau, BMS-Advisory Board, TARGET-IBD-Steering Committee. David T. Rubin: Consultant: AbbVie, Abgenomics, Allergan, Inc., Biomica, Boehringer Ingelheim, Ltd., Bristol-Myers Squibb, Celgene Crop/Syneos, Check-cap, Dizal Pharmaceuticals, GalenPharma/Atlantica, Genentech/Roche, Gilead Sciences, Ichnos Sciences S.A., GSK, InDex Pharmaceuticals, Janssen Pharmaceuticals, Lilly, Narrow River Mgmt, Pfizer, Prometheus Laboratories, Reistone, Shire, Takeda and Techlab, Inc.. Grant support from AbbVie, Genentech/Roche, Janssen Pharmaceuticals, Prometheus Laboratories, Shire and Takeda. Stock options at Abgenomics and Biomica. Board of Trustees at American College of Gastroenterology. Co-Founder, CFO of Cornerstones Health, Inc. (non-profit). Co-Founder of GoDuRn, LLC. Marla C. Dubinsky: Consultant: Pfizer, Janssen, Abbvie, Celgene, Salix, Takeda, Prometheus Labs, Arena, Genentech, Lilly. Research support: Pfizer, Abbvie, Janssen. Miguel Regueiro: Consulting fees from Abbvie, Janssen, UCB, Takeda, Pfizer, Miraca Labs, Amgen, Celgene, Seres, Allergan, Genentech, Gilead, Salix, Prometheus, Lilly, Target RWE. Research support from Abbvie, Janssen, Takeda, Pfizer. Derek Gazis: employee of Target RWE. Julie M. Crawford: employee of Target RWE. Millie D. Long: Consulting fees from AbbVie, Pfizer, Janssen, Takeda, Prometheus, Salix, UCB, Target RWE. Research support from Takeda and Pfizer.
